Wetenschappelijke publicaties van Bordet

Wetenschappelijke publicaties van Bordet

  • Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study.

  • Auteurs Danieli R, Mileva M, Marin G, Kristanto P, Delbart W, Vanderlinden B, Wimana Z, Hendlisz A, Levillain H, Reynaert N, Flamen P, Karfis I
  • Auteurs (entité) VANDERLINDEN BRUNO
  • Revue EJNMMI Res
  • Date de publication 2024-11
Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study.

  • Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study.

  • Auteurs Danieli R, Mileva M, Marin G, Kristanto P, Delbart W, Vanderlinden B, Wimana Z, Hendlisz A, Levillain H, Reynaert N, Flamen P, Karfis I
  • Auteurs (entité) KARFIS IOANNIS
  • Revue EJNMMI Res
  • Date de publication 2024-11
Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study.

  • Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study.

  • Auteurs Danieli R, Mileva M, Marin G, Kristanto P, Delbart W, Vanderlinden B, Wimana Z, Hendlisz A, Levillain H, Reynaert N, Flamen P, Karfis I
  • Auteurs (entité) FLAMEN PATRICK
  • Revue EJNMMI Res
  • Date de publication 2024-11
Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study.

  • Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study.

  • Auteurs Danieli R, Mileva M, Marin G, Kristanto P, Delbart W, Vanderlinden B, Wimana Z, Hendlisz A, Levillain H, Reynaert N, Flamen P, Karfis I
  • Auteurs (entité) MARIN GWENNAELLE
  • Revue EJNMMI Res
  • Date de publication 2024-11
Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study.

  • Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial.

  • Auteurs Rediti M, Venet D, Joaquin Garcia A, Maetens M, Vincent D, Majjaj S, El-Abed S, Di Cosimo S, Ueno T, Izquierdo M, Piccart M, Pusztai L, Loi S, Salgado R, Viale G, Rothé F, Sotiriou C
  • Auteurs (entité) PICCART MARTINE
  • Revue Nat Commun
  • Date de publication 2024-11
Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial.

  • Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial.

  • Auteurs Rediti M, Venet D, Joaquin Garcia A, Maetens M, Vincent D, Majjaj S, El-Abed S, Di Cosimo S, Ueno T, Izquierdo M, Piccart M, Pusztai L, Loi S, Salgado R, Viale G, Rothé F, Sotiriou C
  • Auteurs (entité) VINCENT DELPHINE
  • Revue Nat Commun
  • Date de publication 2024-11
Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial.

  • Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial.

  • Auteurs Rediti M, Venet D, Joaquin Garcia A, Maetens M, Vincent D, Majjaj S, El-Abed S, Di Cosimo S, Ueno T, Izquierdo M, Piccart M, Pusztai L, Loi S, Salgado R, Viale G, Rothé F, Sotiriou C
  • Auteurs (entité) MAJJAJ SAMIRA
  • Revue Nat Commun
  • Date de publication 2024-11
Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial.

  • Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial.

  • Auteurs Rediti M, Venet D, Joaquin Garcia A, Maetens M, Vincent D, Majjaj S, El-Abed S, Di Cosimo S, Ueno T, Izquierdo M, Piccart M, Pusztai L, Loi S, Salgado R, Viale G, Rothé F, Sotiriou C
  • Auteurs (entité) SOTIRIOU CHRISTOS
  • Revue Nat Commun
  • Date de publication 2024-11
Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial.

  • Prognostic and predictive implications of sterile alpha motif and HD domain-containing protein 1 (SAMHD1) expression in breast cancer.

  • Auteurs Kouvaraki M, Zerdes I, Sifakis EG, Sarafidis M, Matikas A, Tzoras E, Kjällquist U, Stathopoulou K, Lövrot J, Alkodsi A, Hartman J, Sotiriou C, Richard F, Hatschek T, Herold N, Bergh J, Rassidakis GZ, Foukakis T
  • Auteurs (entité) SOTIRIOU CHRISTOS
  • Revue Int J Cancer
  • Date de publication 2024-12
Prognostic and predictive implications of sterile alpha motif and HD domain-containing protein 1 (SAMHD1) expression in breast cancer.
Erasme hospital

Erasmusziekenhuis

Bekijk alle wetenschappelijke publicaties van Erasmus

Wetenschappelijke publicaties van Erasmus
Huderf hospital

Queen Fabiola Kinderziekenhuis

Bekijk alle wetenschappelijke publicaties van het Koningin Fabiola Kinderziekenhuis

Wetenschappelijke publicaties van het Koningin Fabiola-Kinderziekenhuis
Bordet hospital

Jules Bordet-instituut

Bekijk alle wetenschappelijke publicaties van Jules Bordet

Wetenschappelijke publicaties van Jules Bordet